Navigating research peptide procurement requires balancing cost efficiency with rigorous analytical verification and manufacturing purity. Understanding the key variables that dictate research-grade CJC price structure empowers laboratories to secure high-purity GHRH analogs without sacrificing experimental reliability.
Navigating research peptide procurement requires balancing cost efficiency with rigorous analytical verification and manufacturing purity. Understanding the key variables that dictate research-grade CJC price structure empowers laboratories to secure high-purity GHRH analogs without sacrificing experimental reliability.
The current market CJC price for research-grade CJC-1295 (with or without DAC) typically ranges from $30 to $90 per vial, depending on chemical modification, sequence length, mass quantity, and analytical validation standards. Lyophilized compounds synthesized in domestic, GMP-compliant facilities with lot-specific HPLC and mass spectrometry verification command higher baseline costs than unverified imported materials.
When evaluating CJC price points, primary investigators must differentiate between raw synthesis overhead and the total cost of analytical quality assurance. A standard 2 mg or 5 mg vial of lyophilized peptide reflects not only amino acid coupling steps, but also downstream preparative purification, counter-ion removal, sterility processing, and comprehensive third-party testing. Procuring peptides purely on low price often introduces hidden variables, such as TFA (trifluoroacetic acid) contamination, sequence truncations, or unacceptable endotoxin loads that compromise in vitro and animal models.
To contextualize how molecular architecture impacts production cost and research utility, it is essential to examine the structural differences between CJC-1295 formulations. CJC-1295 is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH), modified at positions 2, 8, 15, and 27 to enhance enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV).
The base sequence, frequently termed Mod GRF 1-29 or CJC-1295 No DAC, possesses a short biological half-life in rodent models (approximately 30 minutes). Conversely, CJC-1295 DAC incorporates a Maleimidopropionic acid linker attached to the C-terminus. This Drug Affinity Complex (DAC) reactive group enables covalent binding to circulating serum albumin upon administration in vivo, extending the elimination half-life to several days in experimental models. Synthesis of the DAC conjugation moiety requires specialized bioconjugation chemistries, directly contributing to a higher average CJC price compared to unmodified Mod GRF 1-29.
The manufacturing cost of growth hormone secretagogues is primarily dictated by solid-phase peptide synthesis (SPPS) efficiency, yield rates, and purification rigor. Synthetic sequences exceeding 20 amino acids experience exponential yield decay with each added residue if side-reactions occur during deprotection or coupling phases.
In the production of high-grade research peptides, crude peptide mixtures containing deletion sequences and stereoisomers must undergo preparative reverse-phase high-performance liquid chromatography (RP-HPLC). Reaching purity levels exceeding 98% requires multiple chromatographic passes and precise fraction collection. Laboratories evaluating supplier pricing must recognize that achieving >99% purity requires significantly higher raw material volumes and specialized columns, directly driving the final CJC price structure.
A low nominal CJC price is meaningless without objective proof of chemical identity and purity. Reliable suppliers provide lot-specific Certificate of Analysis (COA) documentation generated by independent ISO 17025 accredited laboratories. Researchers should inspect COAs for two core analytical techniques: RP-HPLC chromatograms and Electrospray Ionization Mass Spectrometry (ESI-MS).
RP-HPLC verifies the optical purity and percentage of the target peak relative to related impurities, while mass spectrometry confirms the exact molecular weight (monoisotopic mass) of the synthesized peptide chain. Additionally, research involving cellular assays or animal models requires stringent bacterial endotoxin testing (LAL assay). At PX1 Research, every batch undergoes double-pass HPLC and ESI-MS validation to ensure strict adherence to published chemical specifications.
Preclinical studies suggest that CJC-1295 functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotrophs. In vitro radioimmunoassay data demonstrate that binding of CJC-1295 stimulates intracellular adenylate cyclase activity, triggering cyclic AMP (cAMP) accumulation and subsequent growth hormone (GH) transcription and release.
Rodent bioassays show that continuous exposure to long-acting GHRH analogs preserves pulsatile GH release patterns while elevating total area under the curve (AUC) for circulating insulin-like growth factor 1 (IGF-1). Investigational literature published in our research library highlights the utility of CJC compounds in investigating somatic growth axes, tissue regeneration cascades, and metabolic signaling pathways in laboratory settings.
When designing comparative secretagogue protocols, researchers frequently assess CJC-1295 alongside structural or functional alternatives in the growth hormone axis. For instance, Sermorelin represents the native 1-29 GHRH fragment without DPP-IV stabilizing substitutions, resulting in rapid enzymatic cleavage in vitro. In contrast, ghrelin receptor agonists like Ipamorelin and GHRP-6 target the Growth Hormone Secretagogue Receptor (GHS-R1a) via a completely independent pathway.
From a procurement perspective, the CJC price profile generally sits slightly higher than basic short-chain peptides like Sermorelin due to the additional chemical modifications required for DPP-IV resistance and optional DAC conjugation. However, combining a GHRH agonist (such as CJC-1295) with a selective ghrelin receptor agonist (such as Ipamorelin) is widely documented in preclinical models to produce a synergistic GH release response greater than either compound administered in isolation.
Proper laboratory handling is critical to protect the integrity of research peptides and maintain long-term stability. Lyophilized CJC vials should be stored upon arrival at -20°C in a dry, dark environment. To prevent moisture condensation on the cake, allow the vial to reach room temperature before reconstitution.
Reconstitution should be performed using sterile bacteriostatic water or sterile normal saline, depending on the requirements of the downstream in vitro or animal assay. Gently introduce the solvent along the glass wall of the vial and swirl smoothly; never vortex energetic peptide solutions. Once reconstituted, liquid solutions should be aliquoted into polypropylene microcentrifuge tubes to prevent repeated freeze-thaw cycles and stored at -80°C for extended stability.
To ensure optimal allocation of research budgets and avoid sub-standard reagents, institutional buyers should utilize a standard verification checklist before placing procurement orders:
1. Direct USA Manufacturing: Confirm the chemical synthesis and lyophilization took place in a certified domestic facility. 2. Public Lot Traceability: Ensure each vial features a clear lot number matching an accessible online COA database. 3. Complete Analytical Suite: Demand high-resolution HPLC chromatograms, mass spectrometry spectra, and quantification of residual trifluoroacetate. 4. Endotoxin Control: Verify endotoxin levels measure below 0.1 EU/mg for sensitive cell culture and in vivo work. 5. Wholesale Support: For large-scale screening studies, inquire through wholesale accounts for bulk lot pricing without compromising verification standards.
What is the typical CJC price range for research-grade material?
High-purity, research-grade CJC-1295 generally costs between $30 and $90 per vial depending on mass quantity, sequence modification (DAC vs. No DAC), and level of analytical validation (HPLC/MS, endotoxin testing).
Why does CJC-1295 DAC cost more than CJC-1295 No DAC?
CJC-1295 DAC requires an additional bioconjugation synthesis step to attach the Maleimidopropionic acid linker to the C-terminus. This extra chemical step and subsequent purification process increase manufacturing costs.
Are PX1 Research CJC peptides manufactured in the USA?
Yes. All PX1 Research peptides are manufactured in ISO-compliant facilities within the USA and undergo third-party purity verification prior to distribution.
What analytical tests verify the purity of CJC-1295?
Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for compound purity and Electrospray Ionization Mass Spectrometry (ESI-MS) for sequence mass confirmation.
Can CJC-1295 be reconstituted in standard sterile water?
For short-term laboratory assays, sterile water or normal saline may be used. For multi-use laboratory procedures requiring microbial preservation over several days, bacteriostatic water containing 0.9% benzyl alcohol is standard.
How does CJC-1295 compare to Sermorelin in mechanism?
Both act as GHRH receptor agonists, but CJC-1295 features four specific amino acid substitutions that resist enzymatic degradation by DPP-IV, extending its half-life relative to native Sermorelin.
What are the recommended storage conditions for lyophilized CJC-1295?
Lyophilized powder should be stored at -20°C for long-term storage (up to 24 months). Reconstituted solution aliquots should be stored at -80°C to prevent degradation.
Does PX1 Research offer bulk pricing for institutional research?
Yes, PX1 Research offers tiered volume pricing and wholesale procurement options for qualified research institutions, laboratories, and universities.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.